

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

Claims 1 to 68. (Canceled)

69. (Amended) A compound ~~according to claim 1~~ selected from the group consisting of:

1-{2-[5-(3-Morpholin-4-yl-propoxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine;

(±)-1-{2-[5-(Tetrahydro-furan-3-yloxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine;

1-{2-[5-(3-Methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine;

1-[2-(5-Isobutoxy-benzoimidazol-1-yl)-quinolin-8-yl]-piperidin-4-ylamine;

1-{2-[5-(Tetrahydro-pyran-4-yloxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the foregoing compounds.

70. (Original) A compound according to claim 69 selected from the group consisting of:

1-{2-[5-(3-Morpholin-4-yl-propoxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine;

(+)-1-{2-[5-(Tetrahydro-furan-3-yloxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine;

(-)-1-{2-[5-(Tetrahydro-furan-3-yloxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the foregoing compounds.

71. (Original) A compound according to claim 70, selected from the group

consisting of:

1-{2-[5-(3-Morpholin-4-yl-propoxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the foregoing compound.

72. (Original) A compound according to claim 69, selected from the group consisting of:

1-{2-[5-(3-Methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the foregoing compound.

73. (Original) A compound according to claim 69, selected from the group consisting of:

1-[2-(5-Isobutoxy-benzoimidazol-1-yl)-quinolin-8-yl]-piperidin-4-ylamine; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the foregoing compound.

74. (Original) A compound according to claim 69, selected from the group consisting of:

1-{2-[5-(Tetrahydro-pyran-4-yloxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the foregoing compound.

75. (Original) A compound according to claim 69, wherein said salt is the benzenesulfonate salt.

76. (Original) A compound according to claim 70, wherein said salt is the benzenesulfonate salt.

77. (Original) A compound according to claim 71, wherein said salt is the benzenesulfonate salt.

78. (Original) A compound according to claim 72, wherein said salt is the benzenesulfonate salt.

79. (Original) A compound according to claim 73, wherein said salt is the benzenesulfonate salt.

80. (Original) A compound according to claim 74, wherein said salt is the benzenesulfonate salt.

81. (Amended) A method for the treatment of abnormal cell growth in a mammal comprising administering to said mammal an amount of a compound of claim [1] 69 that is effective in treating abnormal cell growth.

82. (Original) A method according to claim 81 wherein said abnormal cell growth is cancer.

83. (Original) A method according to claim 82 wherein said cancer is selected from lung cancer, bone cancer, pancreatic cancer, gastric, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, gynecological, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, squamous cell, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain, pituitary adenoma, or a combination of one or more of the foregoing cancers.

84. (Original) A method according to claim 83, wherein said cancer is selected from the group consisting of brain, squamous cell, bladder, gastric, pancreatic, breast, head, neck, oesophageal, prostate, colorectal, lung, renal, kidney, ovarian, gynecological and thyroid cancer.

85. (Original) A method according to claim 84, wherein said cancer is selected from the group consisting of prostate, breast, lung, colon and ovarian cancer.

86. (Original) A method according to claim 85, wherein said cancer is selected from the group consisting of prostate, breast, and lung cancer.

87. (Original) A method according to claim 86, wherein said breast cancer is metastatic breast cancer.

88. (Original) A method according to claim 86, wherein said lung cancer is non-small cell lung cancer.

89. (Original) A method according to claim 81, wherein said abnormal cell growth is non-cancerous.

90. (Original) A method according to claim 89, wherein non-cancerous abnormal cell growth is benign hyperplasia of the skin or prostate.

91. (Amended) A method for the treatment of vasculogenesis, restenosis, atherosclerosis or angiogenesis in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of ~~formula 1~~ claim 69 or a pharmaceutically acceptable salt, prodrug or hydrate 1 that is effective in treating vasculogenesis, restenosis, atherosclerosis or angiogenesis.


92. (Original) The method of claim 91, wherein said method is for treating vasculogenesis or angiogenesis.

93. (Amended) A method for the treatment of a hyperproliferative disorder in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of ~~formula 1~~ claim 69, or a pharmaceutically acceptable salt, prodrug or hydrate in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens.

94. (Amended) A pharmaceutical composition for the treatment of abnormal cell growth in a mammal comprising an amount of a compound of claim [1] 69 that is effective in treating abnormal cell growth, and a pharmaceutically acceptable carrier.

95. (Original) The pharmaceutical composition of claim 94 wherein said abnormal cell growth is cancer.

96. (Amended) A process of preparing a compound of the formula 1




or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof, wherein

each  $R^1$ ,  $R^2$ , and  $R^3$  is independently selected from H,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_6$  cycloalkyl, halo, cyano,  $CF_3$ , difluoromethoxy, trifluoromethoxy,  $OC_1$ - $C_6$  alkyl,  $OC_3$ - $C_6$  cycloalkyl, and  $NR^7R^8$ ;

wherein  $R^4$  is  $-(CR^5R^6)_nH$ , or  $-(CR^5R^6)_m$  (4 to 10 membered heterocyclic), wherein n is an integer ranging from 1 to 5, wherein m is an integer ranging from 0 to 5, wherein said 4 to 10 membered heterocyclic when aromatic is optionally substituted by 1 to 3  $R^1$  substituents, and wherein said 4 to 10 membered heterocyclic when non-aromatic is optionally substituted by 1 to 3  $R^7$  substituents ~~substituents~~ substituents at any position and optionally substituted by 1 to 3  $R^9$  substituents at any position not adjacent to or directly attached to a heteroatom; wherein each  $R^5$  and  $R^6$  is independently selected from H or  $C_1$ - $C_6$  alkyl;

wherein each  $R^7$  and  $R^8$  is independently selected from H,  $C_1$ - $C_6$  alkyl, and  $C_3$ - $C_6$  cycloalkyl; and

wherein each  $R^9$  is independently selected from halo, cyano,  $CF_3$ , difluoromethoxy, trifluoromethoxy,  $OC_1$ - $C_6$  alkyl,  $OC_3$ - $C_6$  cycloalkyl, and  $NR^7R^8$  which comprises treating a compound of the formula 2



wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined above for the compound of formula 1 with an acid to give a compound of the formula 1.